{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:43:36Z","timestamp":1793882616583,"version":"4.7.0"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Human hepatitis B virus (HBV) is a small enveloped DNA virus with a complex life cycle. It is the causative agent of acute and chronic hepatitis. HBV can resist immune system responses and often causes persistent chronic infections. HBV is the leading cause of liver cancer and cirrhosis. Interferons (IFNs) are cytokines with antiviral, immunomodulatory, and antitumor properties. IFNs are glycoproteins with a strong antiviral activity that plays an important role in adaptive and innate immune responses. They are classified into three categories (type I, II, and III) based on the structure of their cell-surface receptors. As an effective drug for controlling chronic viral infections, Type I IFNs are approved to be clinically used for the treatment of HBV infection. The therapeutic effect of interferon will be enhanced when combined with other drugs. IFNs play a biological function by inducing the expression of hundreds of IFN-stimulated genes (ISGs) in the host cells, which are responsible for the inhibiting of HBV replication, transcription, and other important processes. Animal models of HBV, such as chimpanzees, are also important tools for studying IFN treatment and ISG regulation. In the present review, we summarized the recent progress in IFN-HBV treatment and focused on its mechanism through the interaction between HBV and ISGs.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1034968","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T02:53:57Z","timestamp":1669863237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["Interferon and interferon-stimulated genes in HBV treatment"],"prefix":"10.3389","volume":"13","author":[{"given":"Qirong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis b virus infection","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100127","article-title":"Viral hepatitis and liver disease. edited by a. j. zuckerman, 1136 pp. new York: Alan r. liss, Inc., 1988. $350.00","volume":"10","author":"Heathcote","year":"1989","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.6.3350-3357.1995","article-title":"The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes","volume":"69","author":"Newbold","year":"1995","journal-title":"J Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis b virus cccdna: Formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antiviral Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an hbv cure: State-of-the-Art and unresolved questions\u2013report of the anrs workshop on hbv cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis b virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.5.685","article-title":"Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis c virus","volume":"4","author":"Foster","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis b: Virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis b: Current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.01.004","article-title":"Interferons and viruses: An evolutionary arms race of molecular interactions","volume":"36","author":"Hoffmann","year":"2015","journal-title":"Trends Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri3210","article-title":"Interferon-inducible effector mechanisms in cell-autonomous immunity","volume":"12","author":"MacMicking","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.12.019","article-title":"A dual role for hepatocyte-intrinsic canonical nf-kappab signaling in virus control","volume":"72","author":"Namineni","year":"2020","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: What do they all do","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu Rev Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis b","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis b virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.1963.tb04673.x","article-title":"Viral hepatitis associated with Sub-human primates","volume":"3","author":"Hillis","year":"1963","journal-title":"Transfusion"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of hbv-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.01.034","article-title":"Hepatitis b virus does not interfere with innate immune responses in the human liver","volume":"154","author":"Suslov","year":"2018","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis b virus genotypes: Global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.060327","article-title":"Response to interferon Alfa is hepatitis b virus genotype dependent: Genotype a is more sensitive to interferon than genotype d","volume":"54","author":"Erhardt","year":"2005","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-009-9140-3","article-title":"Hbeag seroconversion as an important end point in the treatment of chronic hepatitis b","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.3099","article-title":"Molecular characteristics and stages of chronic hepatitis b virus infection","volume":"15","author":"Shi","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1497","article-title":"Hepatitis b surface antigen seroclearance during chronic hbv infection","volume":"15","author":"Chu","year":"2010","journal-title":"Antivir Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis b infection: A review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/cells9092023","article-title":"Intracellular trafficking of hbv particles","volume":"9","author":"Jiang","year":"2020","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26125","article-title":"A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis b virus a-determinant","volume":"57","author":"Sureau","year":"2013","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.3.2052-2057.1999","article-title":"Infection process of the hepatitis b virus depends on the presence of a defined sequence in the pre-S1 domain","volume":"73","author":"Le Seyec","year":"1999","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis b and d virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis b virus: Advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2022.2028483","article-title":"Pathogenicity and virulence of hepatitis b virus","volume":"13","author":"Chuang","year":"2022","journal-title":"Virulence"},{"key":"B32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: A pleiotropic keystone in the hbv lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antiviral Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-092818-015508","article-title":"The hepatitis b virus envelope proteins: Molecular gymnastics throughout the viral life cycle","volume":"7","author":"Seitz","year":"2020","journal-title":"Annu Rev Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.06.093","article-title":"Cell and animal models for studying hepatitis b virus infection and drug development","volume":"156","author":"Hu","year":"2019","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0431-x","article-title":"Samd4 family members suppress human hepatitis b virus by directly binding to the smaug recognition region of viral rna","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.656353","article-title":"Antiviral activity of interferon alpha-inducible protein 27 against hepatitis b virus gene expression and replication","volume":"12","author":"Ullah","year":"2021","journal-title":"Front Microbiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.9.6467","article-title":"The level of hepatitis b virus replication is not affected by protein Isg15 modification but is reduced by inhibition of Ubp43 (Usp18) expression","volume":"181","author":"Kim","year":"2008","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.011","article-title":"Hepatitis delta Co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to hbv mono-infection","volume":"63","author":"Giersch","year":"2015","journal-title":"J Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02580-20","article-title":"Distinct cytokine profiles correlate with disease severity and outcome in longitudinal studies of acute hepatitis b virus and hepatitis d virus infection in chimpanzees","volume":"11","author":"Engle","year":"2020","journal-title":"mBio"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i1.104","article-title":"The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis b virus infection","volume":"13","author":"Menne","year":"2007","journal-title":"World J Gastroenterol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13811","article-title":"Transbody against virus core protein potently inhibits hepadnavirus replication in vivo: Evidence from a duck model of hepatitis b virus","volume":"174","author":"Li","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/hep.25954","article-title":"Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis b","volume":"57","author":"Fletcher","year":"2013","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.10.5757","article-title":"Isolation of a hepadnavirus from the woolly monkey, a new world primate","volume":"95","author":"Lanford","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/v13050777","article-title":"Animal models of hepatitis b virus infection-success, challenges, and future directions","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.766534","article-title":"In vivo mouse models for hepatitis b virus infection and their application","volume":"12","author":"Du","year":"2021","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021469","article-title":"The chimpanzee model for hepatitis b virus infection","volume":"5","author":"Wieland","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104898","article-title":"Animal models for the study of human hepatitis b and d virus infection: New insights and progress","volume":"182","author":"Burwitz","year":"2020","journal-title":"Antiviral Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitis b: Public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J Hepatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: Success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01087-12","article-title":"Viral-Load-Dependent effects of liver injury and regeneration on hepatitis b virus replication in mice","volume":"86","author":"Tian","year":"2012","journal-title":"J Virol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02510-06","article-title":"Deamination-independent inhibition of hepatitis b virus reverse transcription by Apobec3g","volume":"81","author":"Nguyen","year":"2007","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/Cmr.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.030","article-title":"Infection courses, virological features and ifn-alpha responses of hbv genotypes in cell culture and animal models","volume":"75","author":"Zhang","year":"2021","journal-title":"J Hepatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/hep.31282","article-title":"Functional comparison of interferon-alpha subtypes reveals potent hepatitis b virus suppression by a concerted action of interferon-alpha and interferon-gamma signaling","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: Time to rethink combination therapy in chronic hepatitis b","volume":"58","author":"Thimme","year":"2013","journal-title":"J Hepatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58847","article-title":"Ifn-alpha inhibits hbv transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccdna minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30497","article-title":"A functional variant in ubiquitin conjugating enzyme E2 L3 contributes to hepatitis b virus infection and maintains covalently closed circular DNA stability by inducing degradation of apolipoprotein b mrna editing enzyme catalytic subunit 3a","volume":"69","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ni.2647","article-title":"Exosomes mediate the cell-to-Cell transmission of ifn-Alpha-Induced antiviral activity","volume":"14","author":"Li","year":"2013","journal-title":"Nat Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.048","article-title":"Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein a-I","volume":"63","author":"Berraondo","year":"2015","journal-title":"J Hepatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00933-15","article-title":"The interferon-inducible protein tetherin inhibits hepatitis b virus virion secretion","volume":"89","author":"Yan","year":"2015","journal-title":"J Virol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023393242","article-title":"Structure, biology, and therapeutic implications of pegylated interferon alpha-2b","volume":"8","author":"Youngster","year":"2002","journal-title":"Curr Pharm Des"},{"key":"B62","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kda): An advance in the treatment of hepatitis b e antigen-positive chronic hepatitis b","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to pegifn Alfa-2a in patients with hbeag-positive chronic hepatitis b: A randomised open-label trial (Osst trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115070-00001","article-title":"Development of pegylated interferons for the treatment of chronic hepatitis c","volume":"15","author":"Kozlowski","year":"2001","journal-title":"BioDrugs"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by kupffer cells limits nk cell activation and therapy response of patients with hbv infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci Transl Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i48.6145","article-title":"Pegylated interferon alpha-2b up-regulates specific Cd8+ T cells in patients with chronic hepatitis b","volume":"16","author":"Chen","year":"2010","journal-title":"World J Gastroenterol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa399","article-title":"Interferon-induced macrophage-derived exosomes mediate antiviral activity against hepatitis b virus through mir-574-5p","volume":"223","author":"Wu","year":"2021","journal-title":"J Infect Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-5391.2010.01100.x","article-title":"Effect of conventional interferon-alpha in patients with hbeag-positive chronic hepatitis b: A systematic review and meta-analysis","volume":"3","author":"Sun","year":"2010","journal-title":"J Evid Based Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12519-019-00303-w","article-title":"Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis b: A real-life cohort study from shanghai, China","volume":"15","author":"Hu","year":"2019","journal-title":"World J Pediatr"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis b e antigen-positive chronic hepatitis b","volume":"119","author":"Wong","year":"1993","journal-title":"A Meta-Analysis Ann Intern Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.057","article-title":"Hepatitis b virus limits response of human hepatocytes to interferon-alpha in chimeric mice","volume":"140","author":"Lutgehetmann","year":"2011","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.06.004","article-title":"Current treatments for chronic hepatitis b virus infections","volume":"18","author":"Zoulim","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon Alfa-2b alone or in combination with lamivudine for hbeag-positive chronic hepatitis b: A randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14897","article-title":"Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis b virus carriers","volume":"41","author":"Wu","year":"2021","journal-title":"Liver Int"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon Alfa-2b alone or in combination with lamivudine for hbeag-positive chronic hepatitis b: A randomised","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01946.x","article-title":"Hbeag-positive chronic hepatitis b: Why do I treat my patients with pegylated interferon","author":"Lau","year":"2009","journal-title":"Liver Int"},{"key":"B77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-Treatment hbcrag and hbsab levels identify durable functional cure after peg-Ifn-Based therapy in patients with chb","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310234","article-title":"Pilot study of combination therapy with ribavirin and interferon Alfa for the retreatment of chronic hepatitis b e antibody-positive patients","volume":"31","author":"Cotonat","year":"2000","journal-title":"Hepatology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26819","article-title":"Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis b not responding to interferon alone: Results of a pilot study","volume":"34","author":"Serfaty","year":"2001","journal-title":"Hepatology"},{"key":"B80","article-title":"Phase 1a safety and pharmacokinetics of nvr 3-778, a potential first-in-Class hbv core inhibitor","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)00175-6","article-title":"Nvr 3-778, a first-in-Class hbvcore inhibitor, alone and in combination with peg-interferon (Pegifn), in treatment-naive hbeag-positive patients: Early reductions in hbv DNA and hbeag","volume":"64","author":"Yuen","year":"2016","journal-title":"J Hepatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2017.10.017","article-title":"Efficacy of nvr 3-778, alone and in combination with pegylated interferon, vs entecavir in Upa\/Scid mice with humanized livers and hbv infection","volume":"154","author":"Klumpp","year":"2018","journal-title":"Gastroenterology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/ijms22031456","article-title":"Combination of entecavir or tenofovir with pegylated interferon-alpha for long-term reduction in hepatitis b surface antigen levels: Simultaneous, sequential, or add-on combination therapy","volume":"22","author":"Yoshida","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27586","article-title":"Adding pegylated interferon to entecavir for hepatitis b e antigen-positive chronic hepatitis b: A multicenter randomized trial (Ares study)","volume":"61","author":"Brouwer","year":"2015","journal-title":"Hepatology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001940","article-title":"Chinese Medicinal herbs for chronic hepatitis b","author":"Liu","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"B86","first-page":"39","article-title":"Traditional Chinese medicine and related active compounds against hepatitis b virus infection","volume":"4","author":"Cui","year":"2010","journal-title":"Biosci Trends"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23384","article-title":"Contemporary clinical research of traditional Chinese medicines for chronic hepatitis b in China: An analytical review","volume":"51","author":"Zhang","year":"2010","journal-title":"Hepatology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112782","article-title":"Antiviral activity of a polysaccharide from radix isatidis (Isatis indigotica fortune) against hepatitis b virus (Hbv) in vitro Via activation of Jak\/Stat signal pathway","volume":"257","author":"Wang","year":"2020","journal-title":"J Ethnopharmacol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314268111","article-title":"Novel antiviral host factor, Tnk1, regulates ifn signaling through serine phosphorylation of Stat1","volume":"111","author":"Ooi","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01611","article-title":"When hepatitis b virus meets interferons","volume":"9","author":"Tan","year":"2018","journal-title":"Front Microbiol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.07.005","article-title":"High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway","volume":"8","author":"Yuliantie","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.01.004","article-title":"The yin and yang of viruses and interferons","volume":"33","author":"Wang","year":"2012","journal-title":"Trends Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.011","article-title":"Inhibition of Stat1 methylation is involved in the resistance of hepatitis b virus to interferon alpha","volume":"85","author":"Li","year":"2010","journal-title":"Antiviral Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.cell.2017.06.042","article-title":"Methyltransferase Setd2-mediated methylation of Stat1 is critical for interferon antiviral activity","volume":"170","author":"Chen","year":"2017","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00334","article-title":"Microrna as type I interferon-regulated transcripts and modulators of the innate immune response","volume":"6","author":"Forster","year":"2015","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e2004086","DOI":"10.1371\/journal.pbio.2004086","article-title":"Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses","volume":"15","author":"Shaw","year":"2017","journal-title":"PLoS Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: A complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201744100","article-title":"Ifitm3 requires an amphipathic helix for antiviral activity","volume":"18","author":"Chesarino","year":"2017","journal-title":"EMBO Rep"},{"key":"B99","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/jir.2010.0099","article-title":"The role of protein kinase r in the interferon response","volume":"31","author":"Pindel","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2018.09.012","article-title":"From apobec to zap: Diverse mechanisms used by cellular restriction factors to inhibit virus infections","volume":"1866","author":"Chemudupati","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.12.009","article-title":"Interferon-inducible Mx2 is a host restriction factor of hepatitis b virus replication","volume":"72","author":"Wang","year":"2020","journal-title":"J Hepatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.634937","article-title":"The functional and antiviral activity of interferon alpha-inducible Ifi6 against hepatitis b virus replication and gene expression","volume":"12","author":"Sajid","year":"2021","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01872","article-title":"Identification of Trim14 as a type I ifn-stimulated gene controlling hepatitis b virus replication by targeting hbx","volume":"9","author":"Tan","year":"2018","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.67","article-title":"Type I ifn augments il-27-Dependent Trim25 expression to inhibit hbv replication","volume":"15","author":"Tan","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e1008338","DOI":"10.1371\/journal.ppat.1008338","article-title":"Interferon-stimulated gene 20 (Isg20) selectively degrades N6-methyladenosine modified hepatitis b virus transcripts","volume":"16","author":"Imam","year":"2020","journal-title":"PLoS Pathog"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01710-12","article-title":"Inhibition of alpha interferon (Ifn-Alpha)-Induced microrna-122 negatively affects the anti-hepatitis b virus efficiency of ifn-alpha","volume":"87","author":"Hao","year":"2013","journal-title":"J Virol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.031","article-title":"Adar1 stimulation by ifn-alpha downregulates the expression of mavs Via rna editing to regulate the anti-hbv response","volume":"29","author":"Li","year":"2021","journal-title":"Mol Ther"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01998-10","article-title":"Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis b virus in human hepatocyte-derived cells","volume":"85","author":"Mao","year":"2011","journal-title":"J Virol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2007.02.003","article-title":"The human 2\u2019-5\u2019oligoadenylate synthetase family: Unique interferon-inducible enzymes catalyzing 2\u2019-5\u2019 instead of 3\u2019-5\u2019 phosphodiester bond formation","volume":"89","author":"Hovanessian","year":"2007","journal-title":"Biochimie"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nri1489","article-title":"Retroviral restriction by apobec proteins","volume":"4","author":"Harris","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1016\/j.celrep.2019.11.041","article-title":"Type-I-Ifn-Stimulated gene Trim5gamma inhibits hbv replication by promoting hbx degradation","volume":"29","author":"Tan","year":"2019","journal-title":"Cell Rep"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14986","article-title":"Antiviral activity of interferon-stimulated gene 20, as a putative repressor binding to hepatitis b virus enhancer ii and core promoter","volume":"35","author":"Park","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.007970","article-title":"Adenosine deaminase acting on rna-1 (Adar1) inhibits hepatitis b virus (Hbv) replication by enhancing microrna-122 processing","volume":"294","author":"Liu","year":"2019","journal-title":"J Biol Chem"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of Nucleos(T)Ide analogue therapy on hepatocarcinogenesis in chronic hepatitis b patients: A propensity score analysis","volume":"58","author":"Kumada","year":"2013","journal-title":"J Hepatol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41423-021-00801-w","article-title":"Sting signaling activation inhibits hbv replication and attenuates the severity of liver injury and hbv-induced fibrosis","volume":"19","author":"Li","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00771-17","article-title":"Activation of stimulator of interferon genes in hepatocytes suppresses the replication of hepatitis b virus","volume":"61","author":"Guo","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B117","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13148-020-00928-z","article-title":"Ifn-alpha confers epigenetic regulation of hbv cccdna minichromosome by modulating Gcn5-mediated succinylation of histone H3k79 to clear hbv cccdna","volume":"12","author":"Yuan","year":"2020","journal-title":"Clin Epigenet"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA118.000735","article-title":"Comprehensive proteomics identification of ifn-Lambda3-Regulated antiviral proteins in hbv-transfected cells","volume":"17","author":"Makjaroen","year":"2018","journal-title":"Mol Cell Proteomics"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.01.006","article-title":"Polymorphisms of interferon-inducible genes oas associated with interferon-alpha treatment response in chronic hbv infection","volume":"89","author":"Ren","year":"2011","journal-title":"Antiviral Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i41.9186","article-title":"Impact of Il28b and oas gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis b virus","volume":"22","author":"Domagalski","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26064","article-title":"Hepatitis b virus polymerase impairs interferon-Alpha-Induced sta T activation through inhibition of importin-Alpha5 and protein kinase c-delta","volume":"57","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00196-19","article-title":"Hepatitis b virus precore protein P22 inhibits alpha interferon signaling by blocking stat nuclear translocation","volume":"93","author":"Mitra","year":"2019","journal-title":"J Virol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3894816","article-title":"Expression of interferon effector gene Sart1 correlates with interferon treatment response against hepatitis b infection","volume":"2016","author":"Li","year":"2016","journal-title":"Mediators Inflammation"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25382","article-title":"Induction of interleukin 6 impairs the anti-hbv efficiency of ifn-alpha in human hepatocytes through upregulation of Socs3","volume":"91","author":"Yang","year":"2019","journal-title":"J Med Virol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/liv.12244","article-title":"Mir146a impairs the ifn-induced anti-hbv immune response by downregulating Stat1 in hepatocytes","volume":"34","author":"Hou","year":"2014","journal-title":"Liver Int"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001668","article-title":"Herc5 E3 ligase mediates isgylation of hepatitis b virus X protein to promote viral replication","volume":"102","author":"Bawono","year":"2021","journal-title":"J Gen Virol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504273102","article-title":"Interferon prevents formation of replication-competent hepatitis b virus rna-containing nucleocapsids","volume":"102","author":"Wieland","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00918-10","article-title":"Interferons accelerate decay of replication-competent nucleocapsids of hepatitis b virus","volume":"84","author":"Xu","year":"2010","journal-title":"J Virol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32314","article-title":"Getting to hbv cure: The promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156","article-title":"Aasld guidelines for treatment of chronic hepatitis b","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis b virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2015.02.001","article-title":"To translate, or not to translate: Viral and host mrna regulation by interferon-stimulated genes","volume":"25","author":"Li","year":"2015","journal-title":"Trends Cell Biol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.051","article-title":"Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis b vaccination","volume":"29","author":"Eleftheriadis","year":"2011","journal-title":"Vaccine"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2019.03.013","article-title":"Induction of humoral and cellular immune response to hbv vaccine can be up-regulated by sting ligand","volume":"531","author":"Ito","year":"2019","journal-title":"Virology"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.26.356048","article-title":"Isg15-dependent activation of the rna sensor Mda5 and its antagonism by the sars-Cov-2 papain-like protease","volume":"6","author":"Liu","year":"2020","journal-title":"bioRxiv"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.8b00823","article-title":"Linked toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses","volume":"5","author":"Albin","year":"2019","journal-title":"ACS Cent Sci"},{"key":"B137","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/cancers10060186","article-title":"Regulation of constitutive interferon-stimulated genes (Isgs) in tumor cells contributes to enhanced antitumor response of Newcastle disease virus-infected tumor vaccines","volume":"10","author":"Takamura-Ishii","year":"2018","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1034968\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T02:54:01Z","timestamp":1669863241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1034968\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":137,"alternative-id":["10.3389\/fimmu.2022.1034968"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1034968","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"article-number":"1034968"}}